Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

J Clin Oncol. 2014 Nov 10;32(32):3684-5. doi: 10.1200/JCO.2014.56.2017. Epub 2014 Sep 15.

Authors

Francesca Valcamonico¹, Fausto Petrelli², Laura Ferrari¹, Vittorio Ferrari¹, Salvatore Grisanti¹, Sandro Barni², Alfredo Berruti³

Affiliations

¹ University of Brescia, Azienda Ospedaliera Spedali Civili, Brescia, Italy.
² Azienda Ospedaliera Treviglio, Treviglio, Italy.
³ University of Brescia, Azienda Ospedaliera Spedali Civili, Brescia, Italy [email protected].

PMID: 25225432
DOI: 10.1200/JCO.2014.56.2017

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary*
Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary*
Diphosphonates / therapeutic use*
Humans
Imidazoles / therapeutic use*
Male
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology*

Substances

Bone Density Conservation Agents
Diphosphonates
Imidazoles